miRNAs as serum biomarkers for Duchenne muscular dystrophy
Top Cited Papers
Open Access
- 21 March 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 3 (5), 258-265
- https://doi.org/10.1002/emmm.201100133
Abstract
Dystrophin absence in Duchenne muscular dystrophy (DMD) causes severe muscle degeneration. We describe that, as consequence of fibre damage, specific muscle‐miRNAs are released in to the bloodstream of DMD patients and their levels correlate with the severity of the disease. The same miRNAs are abundant also in the blood of mdx mice and recover to wild‐type levels in animals ‘cured’ through exon skipping. Even though creatine kinase (CK) blood levels have been utilized as diagnostic markers of several neuromuscular diseases, including DMD, we demonstrate that they correlate less well with the disease severity. Although the analysis of a larger number of patients should allow to obtain more refined correlations with the different stages of disease progression, we propose that miR‐1, miR‐133, and miR‐206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans. Despite many different DMD therapeutic approaches are now entering clinical trials, a unifying method for assessing the benefit of different treatments is still lacking.Keywords
This publication has 29 references indexed in Scilit:
- North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophyNeuromuscular Disorders, 2010
- MicroRNAs Involved in Molecular Circuitries Relevant for the Duchenne Muscular Dystrophy Pathogenesis Are Controlled by the Dystrophin/nNOS PathwayCell Metabolism, 2010
- Progress in therapeutic antisense applications for neuromuscular disordersEuropean Journal of Human Genetics, 2009
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker researchJournal of Clinical Pathology, 2008
- Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Distinctive patterns of microRNA expression in primary muscular disordersProceedings of the National Academy of Sciences of the United States of America, 2007
- Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohortAmerican Journal of Medical Genetics Part A, 2005
- Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's or Becker's Muscular DystrophyNew England Journal of Medicine, 1988